Published in:
01-02-2004 | Poster presentation
Drotrecogin alfa (activated) does not impair platelet receptor expression in vitro
Authors:
T Schuerholz, I Kornau, L Friedrich, B Juettner, H Elsner, D Scheinichen
Published in:
Critical Care
|
Special Issue 1/2004
Login to get access
Excerpt
During the past decade attempts were made to find a drug decreasing the high mortality in severe sepsis and septic shock. Recently, a trial showed a significant reduction in mortality under the application of drotrecogin alfa (activated) (Xigris; Eli Lilly, Bad Homburg, Germany) (recombinant human activated protein C [APC]). Severe thrombocytopenia might be a risk factor for serious bleeding under this therapy. The median plasma concentration of APC at steady state is 0.045 μg/ml. A previous study revealed an APC-dependent reduction of CD62P on the platelet surface exclusively after activation with recombinant tissue factor. However, the amounts of APC used were high, above steady-state concentrations (0.5–20 μg/ml), and the effect of APC in therapeutic concentrations on the expression of platelet receptors has not yet been studied systematically. …
